Dr. Craig Crews, Ph.D., is the foremost pioneer in the field of targeted protein degradation and founded Arvinas in 2013. He is the John C. Malone Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University. During his 25 years at Yale, Dr. Crews’ laboratory has pioneered the use of small molecules to control intracellular protein levels, which has resulted in the formation of multiple successful biotech companies. In 2003, he co-founded Proteolix, Inc., whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Dr. Crews has served on several editorial boards, including as editor of Cell Chemical Biology (2008-2018). Dr. Crews has received numerous awards and honors, including the 2013 CURE Entrepreneur of the Year Award, 2014 Ehrlich Award for Medicinal Chemistry, 2015 Yale Cancer Center Translational Research Prize, a NIH R35 Outstanding Investigator Award (2015), the AACR Award for Chemistry in Cancer Research (2017), Khorana Prize from the Royal Society of Chemistry (2018), Pierre Fabre Award for Therapeutic Innovation (2018), and the Pharmacia-ASPET Award for Experimental Therapeutics (2019). In 2019, he was named an American Cancer Society Professor.
Dr. Crews received his B.A. in Chemistry from the University of Virginia and his Ph.D. in Biochemistry from Harvard University.